Atlantic Health System is now enrolling hospitalized patients with severe COVID-19 in the PRE-VENT phase 3 multicenter trial of pacritinib, an investigational cancer drug. Part of its new COVID-19 Research Program, the prominent New Jersey-based health system now...
ARDS
Icahn School of Medicine at Mount Sinai Drives Collaborative Investigation into use of Nintedanib in COVID-19 Patients with Fibrosing ILD
New York City’s preeminent Icahn School of Medicine at Mount Sinai, Department of Medicine’s Clinical Trials Office (CTO) and collaborative partner Boehringer Ingelheim, the world’s largest privately held pharmaceutical company based in Germany, announced that the...
Physician in Savannah, Georgia, Embraces Investigational Regenerative Acellular-based Therapy to Treat COVID-19 Long Haulers on FDA Expanded Access Protocol
With over 12 million COVID-19 cases and growing, some physicians become ever more open and innovative in their quest to treat their patients. Take Dr. Allen Meglin, practicing in Savannah, Georgia, who now has internalized the need to deal with the frightening next...
Novartis Pays $50m Upfront Cash for License and Stock in Mesoblast to Access Mesenchymal Stromal Cells Regenerative Therapy Platform
Novartis recently inked an exclusive worldwide license and collaboration agreement with regenerative therapy venture Mesoblast to develop, commercialize and manufacture remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS), including that...
Temple University Team Works on Developing Algorithms that Can Predict the COVID-19 based Cytokine Storm
Temple University’s Lewis Katz School of Medicine recently published the results of a study that risk stratifies COVID-19 patients—identifying those individuals most at risk of experiencing life-threatening reactions such as the cytokine storm. The Philadelphia-based...
Successful COVID-19 Compassionate Use Study Using Monoclonal Antibody Narsoplimab with Univ. Milan Principal Investigator
Omeros Corporation (Nasdaq: OMER) announced that the results of a compassionate-use study evaluating the company’s investigational monoclonal antibody, narsoplimab, targeting mannan-binding lectin-associated serine protease-2 (MASP-2), in the treatment of...
Real World Observation Out of Utah’s Intermountain Healthcare: COVID-19 Can Cause Heart Disease
Intermountain Healthcare, a Utah-based healthcare system, is widely recognized as a leader in transforming healthcare by using evidence-based best practices to consistently deliver high-quality outcomes and sustainable costs. Recently, Kirk U. Knowlton, MD,...
Patients in Touch with TrialSite Seeking Help to Access RLF-100 While FDA Approved IND
TrialSite News, an online digital media and social engagement platform dedicated to open, accessible, and transparent clinical research, receives messages from patients on a daily basis. With COVID-19, an urgency has raised the stakes of each and every communication....
FDA Approves EC-18 for Phase 2 Clinical Trials Targeting ARDS in COVID-19 Patients: Led by Duke Infectious Disease Expert Dr. Cameron Robert Wolfe
South Korean-based Enzychem Lifesciences (KOSDAQ: 183490) just announced that the US Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to evaluate its lead therapeutic candidate EC-18, in a Phase 2 clinical trial in...
At-Home Decentralized COLCORONA Trial Investigates if Colchicine Keeps COVID-19 Symptoms from Progressing to Reduce Hospitalization & Death
There is presently no available, FDA-approved medicine that can be administered at a patient’s home that can prevent the negative progression of SARS-CoV-2 symptoms leading to hospitalization and potentially death. Can a widely available, generic drug used for gout...
Piedmont Participating in Large Global Trial Investigating Ventilation, ECMO Use on COVID-19 Patients
Piedmont Healthcare is participating in a large international clinical trial to study the effects of ventilation and Extracorporeal Membrane Oxygenation, or ECMO, in the critical care setting on patients suffering from the combination of COVID-19 and Acute Respiratory...
Korean Researchers Identify Interferon Type 1 Key for COVID-19 Cytokine Storm New Targets
The Korea Advanced Institute of Science and Technology reports a joint team of researchers discovered the cause of hyper-inflammatory response in COVID-19 patients. Interferon type 1 could hold a key to advanced solutions for severe COVID-19 cases associated with the...
DynPort Vaccine Company (part of General Dynamics) Partners with Biotech to Investigate ILR201104 in COVID-19 Patients with ARDS
Yet another group is targeting the important (and deadly) topic of COVID-19 Acute Respiratory Distress Syndrome (ARDS) as this remains one of the most common ways patients afflicted with severe to critical SARS-CoV-2 pass away. To lower the death rate, a number of...
Could COVID-19 Complications Originate from NET-like Inflammatory Response? “The U” Licenses IP to Spinoff PEEL Therapeutics
University of Utah (“The U”) research reveals that an overactive defense response may lead to increased blood clotting, disease severity, and death from COVID-19. A team from the University of Utah Health and PEEL Therapeutics in collaboration with Cold Spring Harbor...
Does Kevzara Failure in COVID-19 Patients Requiring Mechanical Ventilation Implicate other Repurposed Autoimmune Drugs in the War on COVID-19?
Regeneron and Sanofi announced that the U.S. Phase 3 clinical trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation failed to meet its primary and key secondary endpoints when the drug was added to best supportive care compared to...
Biophytis Plans Phase 2/3 Clinical Trial Investigating the Efficacy of Sarconeos (BIO101) in COVID-19 Patients with ARDS
Biophytis SA (ALBPS) is a clinical stage biotechnology company specializing in the development of drug candidates for the treatment of aged related diseases, such as neuromuscular diseases. The U.S. Food and Drug Administration (FDA) accepted its investigational new...
Eli Lilly’s Baricitinib Shows Promise as Therapy to Prevent Deadly COVID-19 Cytokine Storms
Four different clinical studies reveal that rheumatoid arthritis drug baricitinib may be effective in preventing cytokine storms—those severe immune system reactions in severe to critical COVID-19 cases—that can lead to patient morbidity and mortality. What is...
Canada Health Greenlights Clinical Trial Investigating NuvOx’s Oxygen Therapeutic as a Treatment for COVID-19-based AHRF
NuvOX Pharma, a Tucson Arizona-based biotechnology company, received the green light in the form of a “No Objection Letter” form Health Canada to initiate a Phase 2a clinical trial investigating NanO2 in COVID-19 patients with acute hypoxic respiratory failure (AHRF)....
UK Gov Approves as U.S. HHS Places Dexamethasone on Treatment Guidelines; Demand Soars & More Data Needed
The government of the United Kingdom (UK) approved dexamethasone, a commonly prescribed steroid treatment, as a COVID-19 therapy thanks to the successful University of Oxford RECOVERY trial evidencing that low doses of the steroid reduce deaths in hospitalized...
Veru Enrolls First Patient in Phase 2 Clinical Trial of Novel Drug, VERU-111, to Combat COVID-19
Veru Inc., an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, announced that it has enrolled the first patient in its Phase 2 clinical trial of VERU-111, a novel microtubule...